276 related articles for article (PubMed ID: 2681118)
1. In-vitro activity of cilofungin (LY121019) in comparison with amphotericin B.
Meunier F; Lambert C; Van der Auwera P
J Antimicrob Chemother; 1989 Sep; 24(3):325-31. PubMed ID: 2681118
[TBL] [Abstract][Full Text] [Related]
2. Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis.
Hall GS; Myles C; Pratt KJ; Washington JA
Antimicrob Agents Chemother; 1988 Sep; 32(9):1331-5. PubMed ID: 3058017
[TBL] [Abstract][Full Text] [Related]
3. Activity of cilofungin (LY121019) against Candida species in vitro.
Odds FC
J Antimicrob Chemother; 1988 Dec; 22(6):891-7. PubMed ID: 3243737
[TBL] [Abstract][Full Text] [Related]
4. In-vitro effects of cilofungin (LY121019), amphotericin B and amphotericin B-deoxycholate on human polymorphonuclear leucocytes.
Van der Auwera P; Meunier F
J Antimicrob Chemother; 1989 Nov; 24(5):747-63. PubMed ID: 2557318
[TBL] [Abstract][Full Text] [Related]
5. In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species.
Smith KR; Lank KM; Dismukes WE; Cobbs CG
Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):588-92. PubMed ID: 1655435
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species.
Spitzer ED; Travis SJ; Kobayashi GS
Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):80-1. PubMed ID: 3132386
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of in vitro antifungal activity of LY121019.
Hobbs M; Perfect J; Durack D
Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):77-80. PubMed ID: 3132385
[TBL] [Abstract][Full Text] [Related]
8. The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species.
Bulo AN; Bradley SF; Kauffman CA
Mycoses; 1989 Jan; 32(1):46-52. PubMed ID: 2747742
[TBL] [Abstract][Full Text] [Related]
9. Fungicidal activity of cilofungin (LY121019) alone and in combination with anticapsin or other antifungal agents.
Pfaller M; Gordee R; Gerarden T; Yu M; Wenzel R
Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):564-7. PubMed ID: 2504601
[TBL] [Abstract][Full Text] [Related]
10. The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species.
Bulo AN; Bradley SF; Kauffman CA
Mycoses; 1989 Mar; 32(3):151-7. PubMed ID: 2733727
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of cilofungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimens.
Hanson LH; Stevens DA
Antimicrob Agents Chemother; 1989 Aug; 33(8):1391-2. PubMed ID: 2802565
[TBL] [Abstract][Full Text] [Related]
12. Retinal toxicity and in vitro efficacy study of cilofungin (LY121019).
Shahsavari M; Peyman GA; Niesman MR
Ophthalmic Surg; 1990 Oct; 21(10):726-8. PubMed ID: 2250858
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of nosocomial isolates of Candida species to LY121019 and other antifungal agents.
Pfaller MA; Wey S; Gerarden T; Houston A; Wenzel RP
Diagn Microbiol Infect Dis; 1989; 12(1):1-4. PubMed ID: 2714066
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro antifungal susceptibility studies with 30 serotype A and B isolates of Candida albicans.
Shadomy S; Shadomy HJ
Diagn Microbiol Infect Dis; 1991; 14(1):21-2. PubMed ID: 2013207
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.
Zhanel GG; Karlowsky JA; Harding GA; Balko TV; Zelenitsky SA; Friesen M; Kabani A; Turik M; Hoban DJ
Antimicrob Agents Chemother; 1997 Apr; 41(4):863-5. PubMed ID: 9087508
[TBL] [Abstract][Full Text] [Related]
16. Comparative susceptibility of four kinds of pathogenic fungi to amphotericin B and amphotericin B methyl ester.
Huston AC; Hoeprich PD
Antimicrob Agents Chemother; 1978 Jun; 13(6):905-9. PubMed ID: 354519
[TBL] [Abstract][Full Text] [Related]
17. Effect of cilofungin on phagocytosis and intracellular killing of Candida albicans by human neutrophils.
Richardson MD; Scott G; Shankland GS
Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):22-6. PubMed ID: 1563379
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of Candida species to cilofungin (LY-121019).
Torres-Rodriguez JM; Carrillo-Muñoz A; Gallach-Bau C; Madrenys N
Mycoses; 1989 Jun; 32(6):316-8. PubMed ID: 2779613
[TBL] [Abstract][Full Text] [Related]
19. Comparative activity in vitro of cilofungin (LY 121019) with other agents used for treatment of deep-seated Candida infections.
Rennie RP; Hellman L
Mycoses; 1989 Mar; 32(3):145-50. PubMed ID: 2733726
[TBL] [Abstract][Full Text] [Related]
20. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.
Ernst EJ; Klepser ME; Pfaller MA
Antimicrob Agents Chemother; 2000 Apr; 44(4):1108-11. PubMed ID: 10722525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
